Fortress Biotech Pref A (FBIOP) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$68.5M

Revenue (quarter)

$18.7M

Revenue growth (year over year)

+14.04%

Gross profit (trailing twelve months)

$44.9M

Gross margin

65.59%

Net income (trailing twelve months)

$141.2M

Net income (quarter)

$602,000.00

Net income growth (year over year)

+105.17%

Net margin

206.22%

Return on equity

99.36%

EPS (trailing twelve months)

$3.25

Book value per share

$4.93

P/E (trailing twelve months)

0.58

Price to book

0.29

Debt to assets

34.93%

Payout ratio

−7.19%

Dividend yield

—

Company profile

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

• Is Fortress Biotech Pref A (FBIOP) profitable?

  Yes. Fortress Biotech Pref A earned $141.2M in net income over the trailing twelve months, a net margin of 206.22%.

• How much revenue does Fortress Biotech Pref A (FBIOP) make?

  Fortress Biotech Pref A generated $68.5M in revenue over the trailing twelve months, up 14.04% year over year.

• What is FBIOP's P/E ratio?

  Fortress Biotech Pref A trades at 0.6 times trailing twelve-month earnings, on an EPS of $3.25.

• How do I buy stock in Fortress Biotech Pref A (FBIOP)?

  FBIOP trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.